Newborns in the neonatal intensive care unit often face serious infections called sepsis. Doctors frequently start strong antibiotics to fight these germs. But using too many of these powerful drugs can lead to resistance and other problems. A team is testing a new approach in five hospitals in the Suqian region of China. These areas face resource limits that make standard care harder to provide. The plan bundles several steps to help doctors use antibiotics only when truly needed. It includes checking risk levels early and reviewing the need for drugs after two to three days. The team also uses a two-tier governance structure to keep everyone on track. They will run monthly cycles to review progress and make adjustments as needed. This method aims to lower the rate of antibiotic use and the number of days patients spend on therapy. The study will also look at whether infections return or if babies pass away during their hospital stay. Safety is a top priority, though no specific side effects have been reported yet because the work is still happening. This project will help other hospitals in similar settings find ways to use these medicines more wisely.
Antibiotic stewardship bundle aims to cut antibiotic use in Chinese NICUsA new plan aims to cut unnecessary antibiotics for sick newborns in China
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Interpret this protocol as hypothesis-generating; no results are available yet.
This is a protocol for a multicenter, before-and-after, interrupted time series quality improvement study designed to evaluate a bundled antimicrobial stewardship program (ASP) in five NICUs in the Suqian region of China, a resource-limited setting. The intervention comprises standardized early-onset sepsis risk stratification, mandatory 48-72 hour antibiotic reassessment, protocolized empirical antibiotic regimens, and a two-tier governance structure supported by monthly Plan-Do-Study-Act cycles. The comparator is a baseline period in 2025.
The primary outcomes are antibiotic use rate and antibiotic utilization rate (days of therapy per 1,000 patient-days). Secondary outcomes include incidence of late-onset sepsis, in-hospital mortality, antibiotic re-initiation rate, and process adherence. The study includes a 12-month baseline period (2025) and a 12-month intervention period (2026-2027).
As this is a protocol, no results are reported. The authors note that the study is ongoing. Safety data, limitations, and funding details are not reported. The practice relevance is that findings will provide evidence to inform scalable antimicrobial stewardship strategies in similar resource-constrained neonatal care settings. Clinicians should await results before applying these strategies.
What this means for you:
A new plan in China aims to reduce antibiotic use for newborns with sepsis while keeping them safe. More on Sepsis
Early postnatal antibiotic exposure increases BPD risk in very preterm infants across 11 studies
Early Antibiotic Exposure Linked to Risks for Very Preterm Infants
This meta-analysis of 11 studies indicates that early postnatal antibiotic exposure is associated with an increased risk of bronchopulmonary…
Early antibiotic use in very preterm infants is linked to higher risks of lung issues, intestinal damage, and mortality.
Meta-analysis shows association between adequate antimicrobial therapy and reduced hospital length of stay
Right Antibiotic Choice Cuts Hospital Stay by Nearly Two Weeks
This meta-analysis of 4158 adult hospitalised patients examines the relationship between adequate empirical antibiotic therapy and clinical …
Choosing the right antibiotic from the start can cut a hospital stay by nearly two weeks for adults with serious infections.
Upadacitinib shows rapid improvement in refractory acrodermatitis continua of Hallopeau
Upadacitinib Shows Promise for Treatment of Chronic Skin Condition
This case report and literature review describes a 54-year-old man with a 13-year history of isolated acrodermatitis continua of Hallopeau (…
A new case report shows how a specific medication helped a man with a rare, long-term skin condition and nail inflammation.
Bleeding, sepsis, and liver impairment each independently raise thrombocytopenia risk in ICU patients
Critical illness factors linked to lower platelet counts in patients
This meta-analysis of 27,147 critically ill patients found that bleeding (OR 3.49), sepsis (OR 2.32), and impaired liver function (OR 1.55) …
New data shows that bleeding, sepsis, and liver issues significantly increase the risk of low platelets in critically ill patients.
View Original Abstract ↓
Antibiotic overuse is prevalent in neonatal intensive care units (NICUs) and is associated with adverse neonatal outcomes and antimicrobial resistance. While antimicrobial stewardship programs (ASPs) have been implemented globally, antibiotic utilization rates remain high in China, particularly in resource-limited regional settings. Evidence indicates that guideline dissemination alone is insufficient to alter established prescribing behaviors, underscoring the need for pragmatic, system-level quality improvement (QI) strategies. This study outlines a multicenter QI initiative designed to optimize antibiotic use in NICUs within a resource-limited region of China.
This ongoing study uses a multicenter, before-and-after interrupted time series (ITS) design across five NICUs in the Suqian region. A bundled ASP intervention is being implemented, comprising standardized early-onset sepsis risk stratification, mandatory 48–72-h antibiotic reassessment, protocolized empirical antibiotic regimens, and a two-tier governance structure supported by monthly Plan–Do–Study–Act cycles. Monthly aggregated data are collected during a 12-month baseline period (2025) and a 12-month intervention period (2026–2027). Primary outcomes are the antibiotic use rate and the antibiotic utilization rate (days of therapy per 1,000 patient-days). Balancing measures include the incidence of late-onset sepsis, in-hospital mortality, and antibiotic re-initiation rate. Process adherence is monitored as a key implementation indicator. Segmented regression ITS analysis and statistical process control charts are used to evaluate the intervention effect.
This study evaluates a pragmatic, workflow-integrated ASP QI model for regional NICUs with limited resources. By integrating standardized clinical pathways, structured reassessment, and continuous data-driven feedback within a multicenter collaborative framework, the intervention aims to safely reduce unnecessary antibiotic exposure. The findings will provide evidence to inform scalable antimicrobial stewardship strategies in similar resource-constrained neonatal care settings.
https://www.chictr.org.cn/, dentifier: ChiCTR2600120301.
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
FDA Approves Dyna-hex 4 (chlorhexidine gluconate) for Healthcare Personnel Handwash
FDA approves Dyna-hex 4 for handwashing and skin cleansing.
The FDA approved Dyna-hex 4 (chlorhexidine gluconate) for healthcare personnel handwash, skin wound cleansing, and general skin cleansing. T…
The FDA approved Dyna-hex 4 (chlorhexidine gluconate) for use as a handwash and skin cleanser in healthcare settings. It helps reduce bacter…
FDA Approves Kaletra (lopinavir/ritonavir) for HIV-1 Infection in Adults and Children
FDA approves new HIV drug Kaletra for adults and children.
FDA approved Kaletra (lopinavir/ritonavir) for treatment of HIV-1 infection in adults and pediatric patients 14 days and older, in combinati…
The FDA approved Kaletra (lopinavir/ritonavir) to treat HIV-1 infection in adults and children aged 14 days and older. It is used with other…
FDA Approves Kaletra (lopinavir/ritonavir) for HIV-1 Infection in Patients 14 Days and Older
FDA approves Kaletra to treat HIV in adults and children 14 days and older.
The FDA approved Kaletra (lopinavir/ritonavir) for HIV-1 infection in adults and pediatric patients 14 days and older, in combination with o…
The FDA approved Kaletra (lopinavir/ritonavir) for HIV-1 infection in adults and children as young as 14 days. It is used with other HIV med…
FDA Approves Dyna-hex 2 (chlorhexidine gluconate) for Surgical Hand Scrub and Healthcare Personnel Handwash
FDA approves Dyna-hex 2 antiseptic for surgical hand scrubs and healthcare handwash.
The FDA approved Dyna-hex 2 (chlorhexidine gluconate) for use as a surgical hand scrub and healthcare personnel handwash. It significantly r…
The FDA approved Dyna-hex 2 (chlorhexidine gluconate) as a surgical hand scrub and healthcare handwash to reduce bacteria on hands and forea…
From Other Specialties
Current molecular and cellular phenotypes do not yet support clinical subtype identification for recurrent pregnancy loss
New research looks at why some pregnancies end early
This mini review examines maternal-fetal interface abnormalities in patients with unexplained recurrent pregnancy loss (URPL). The authors c…
Doctors are looking for better ways to understand and treat the reasons behind repeated pregnancy loss.
TNF inhibitors may be effective for juvenile idiopathic arthritis in patients with DiGeorge syndrome
Biologic treatments show promise for children with DiGeorge syndrome
This case report and literature review examines the management of juvenile idiopathic arthritis (JIA) in children with DiGeorge syndrome (DG…
Children with both DiGeorge syndrome and juvenile idiopathic arthritis may find relief from joint pain using specific biologic medications.
mHealth apps reduce HbA1c by 0.39% in type 2 diabetes across 19 RCTs
Mobile Health Apps Help Manage Blood Sugar in Type 2 Diabetes
This meta-analysis of 19 RCTs with 2,166 participants found that mobile health (mHealth) app interventions significantly reduced HbA1c (MD -…
Using mobile health applications can help people with type 2 diabetes lower their blood sugar levels and improve their overall quality of li…
Oral-health promotion improves outcomes for adults with type 2 diabetes when guidance is provided
Oral health care is often missed in type 2 diabetes management
This scoping review of 9 peer-reviewed studies examines oral-health promotion and prevention in adults with type 2 diabetes. The authors fin…
Many people with type 2 diabetes do not know their oral health is at risk, and doctors often provide inconsistent guidance on how to manage …